Arkos Monitoring Patient Care
Posted on: Tuesday, 14 March 2006, 12:00 CST
PMSI-Tmesys, a provider of pharmacy services, has introduced software to help payors control medication costs and monitor patient care.
The Arkos Risk Management System has been designed to model drug utilization, taking into account risk assessment and pharmacy intervention programs. Using Arkos, PMSI-Tmesys is confident its clinical pharmacists will be able to identify the probability of adverse drug reactions and alert physicians and payors so that care can be modified before problems occur.
Through a computerized screening process, Arkos evaluates each patient's drug and medical history to assess risk status. Clinicians then analyze the data to spot cases that could present future medical complications and need be directed into early case management for closer monitoring. The information is communicated to the payor and an intervention program is recommended.
PMSI-Tmesys says that its drug utilization software will allow it to spot issues before they become larger, more expensive healthcare problems. For example, the Arkos system could flag a patient record of an injured worker who showed risk factors for heart problems and who was taking medication that could heighten the chances of a heart attack or stroke.
Source: Datamonitor
Related Articles
- Management Strategies For High Risk Stroke Patients Are Poor In A Majority Of Cases
- Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
- Molecules May ID at-Risk Leukemia Patients
- Aspirin Useful in Reducing Stroke Risk of Patients With Establishedheart Disease: Study
- Drug Maker Cites 2 More Patient Deaths
- Seniors at Higher Risk for Medication-Related Problems
- Bird Flu Virus Found Resistant to Antiviral Drug Tamiflu in Vietnamese Patient
- Low-cost alternative drugs can help patients with problems controlling blood pressure
- Trial Shows New Drug May Help Cancer Patients Who Need Stem Cell Transplants
- Patient Deaths Decline in Early Studies of New Cancer Drugs More-Targeted Drugs, More Emphasis on Patient Safety Cited in Minimizing Risk
User Comments (0)

RSS Feeds